Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands Expecting Impactful Near-Term Launches, Including Fast-Acting Meloxicam and Low-Dose Estrogen Weekly Patch in the U.S., and Pitolisant and Effexor® for GAD in Japan Unlocking Long-Term Value Through Potential Blockbusters Selatogrel and Cenerimod Strong Cash Flow Generation Enabling Capital Return and Disciplined Business Development Providing Long-Term Targets for Sustained Growth Through 2030 PITTSBURGH, March 19, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will host its Investor Event today, where members of the executive leadership team will outline the Company's strategic vision, key drivers and financial framework expected to deliver sustained revenue and earnings growth through 2030. Executive Commentary "Over the past several years, we have taken decisive actions to strengthen the foundation of Viatris by simplifying the portfolio, strengthening the balance sheet and stabilizing the base business," said Scott A.
